Clinical and Diagnostic Value of Inflammatory Bowel Diseases' Serological Markers in Children (Literature Review)
https://doi.org/10.15690/pf.v20i4.2605
Abstract
The prevalence of inflammatory bowel diseases (IBD) is increasing worldwide. Crohn's disease (CD) and ulcerative colitis (UC) are characterized by chronic progressive course, high frequency of complications, and high risk of surgical treatment. Up to 50% of CD patients die due to its complications, and quarter of these patients require at least one surgery during their lifetime. IBD patients have 8 times higher risk of colorectal and small intestine cancer. IBD diagnosis can be established during childhood in 25% of cases. Early intensified therapy of individual patient groups could significantly reduce complications and surgical treatment rates. However, nowadays there are no reliable prognostic criteria for the unfavorable course of IBD. The aim of this review is to define the most studied IBD serological markers and to evaluate immune reactivation role in CD and UC course in children.
Supporting agencies: Not specified.
About the Authors
Aelita A. Kamalova
Kazan State Medical University; Children's Republican Clinical Hospital
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD, Professor.
Kazan
Disclosure of interest:
None
Marina A. Khanafina
Kazan State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
MD.
49 Butlerova Str., Kazan, 420012.
tel.: +7 (986) 931-79 46
Disclosure of interest:
None
Galina A. Garina
Kazan State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
MD.
Kazan
Disclosure of interest:
None
References
1. Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Dig Med Res. 2020;3:48. doi: https://doi.org/10.21037/dmr-20-149
2. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942-951. doi: https://doi.org/10.1097/MOG.0b013e32836229fb
3. Kornienko EA, Khavkin AI, Fedulova EN, et al. Draft recommendations of the russian society of pediatric gastroenterology, hepatology and nutrition on diagnosis and treatment of Crohn's disease in children. Experimental and Clinical Gastroenterology. 2019;(11):100-134. (In Russ). doi: 10.31146/1682-8658-ecg-171-11-100-134
4. Alhasov AB, Bataev SM, Belmer SD, et al. Detskaya gastroenterologiya: National guide. Series “National guides”. Moscow: GEOTAR-Media; 2022. pp. 391-433. (In Russ). doi: https://doi.org/10.33029/9704-6990-3-GAS-2022-1-864
5. Vakhitov TYa, Kononova SV, Demyanova EV, et al. Identification of candidate biomarkers for inflammatory bowel disease using non-targeted serum metabolomics. Pediatric Nutrition. 2022;20(6):21-32. (In Russ). doi: https://doi.org/10.20953/1727-5784-2022-6-21-32
6. Ashton JJ, Versteegh HP, Batra A, et al. Colectomy in pediatric ulcerative colitis: A single center experience of indications, outcomes, and complications. J Pediatr Surg. 2016;51(2):277-281. doi: https://doi.org/10.1016/j.jpedsurg.2015.10.077
7. Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353-1365. doi: https://doi.org/10.1111/apt.16060
8. Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep. 2020;22(8):36. doi: https://doi.org/10.1007/s11894-020-00773-3
9. Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci. 2019;20(10):2529. doi: https://doi.org/10.3390/ijms20102529
10. Akpunonu B, Hummell J, Akpunonu JD, Ud Din S. Capsule endoscopy in gastrointestinal disease: Evaluation, diagnosis, and treatment. Cleve Clin J Med. 2022;89(4):200-211. doi: https://doi.org/10.3390/ijms20102529
11. Likutov AA, Veselov VV, Pritula NA, et al. Possibilities of videocapsule endoscopy in the diagnosis of inflammatory bowel diseases. Endoscopic Surgery. 2017;23(2):2327. (In Russ). doi: https://doi.org/10.17116/endoskop201723223-27
12. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi: https://doi.org/10.1093/ecco-jcc/jjy113
13. Sovalkin VI, Bikbavova GR, Emel'yanova YuA. The modern view of the pathogenesis and laboratory diagnostics of ulcerative colitis (literatire review). The Russian Archives of Internal Medicine. 2017;7(4):252-259. (In Russ). doi: https://doi.org/10.20514/2226-6704-2017-7-4-252-259
14. Sakurai T, Saruta M. Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. 2023;104(1):30-41. doi: https://doi.org/10.1159/000527846
15. Alkhasov AB, Bekhtereva MK, Volynets GV, et al. Bolezni kishechnika u detei. Bel'mer SV, Razumovskii AYu, Khavkin AI, eds. Moscow: Medpraktika-M; 2018. Vol. 1. 435 p. (In Russ).
16. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105-1111. doi: https://doi.org/10.1016/j.cgh.2008.04.032
17. Steiner CA, Berinstein JA, Louissaint J, et al. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2022;20(4):817-846.e10. doi: https://doi.org/10.1016/j.cgh.2021.05.054
18. Yang W, Yu T, Cong Y. Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice. J Vis Exp. 2021;(178). doi: https://doi.org/10.3791/63293
19. Pang Y, Ruan H, Wu D, et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin Immunol. 2020;16:37. doi: https://doi.org/10.1186/s13223-020-00433-1
20. Liu X, Guo D, Li X, et al. Value of combined detection of PCA, ANCA, ASCA, AGA and ANA in early diagnosis of Gastrointestinal Diseases. Pak J Med Sci. 2022;38(1):227-231. doi: https://doi.org/10.12669/pjms.38.1.4682
21. Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006;12(5):389-394. doi: https://doi.org/10.1097/01.MIB.0000218765.84087.42
22. Wang H, Demirkan G, Bian X, et al. Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B‘, as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach. J Crohns Colitis. 2017;11(7):848-856. doi: https://doi.org/10.1093/ecco-jcc/jjx019
23. Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55(4):429-435. doi: https://doi.org/10.1097/MPG.0b013e318256b516
24. Hanzel J, Ma C, Casteele NV, et al. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021;81(3):333-347. doi: https://doi.org/10.1007/s40265-020-01460-3
25. Rieder F, Hahn P, Finsterhoelzl L, et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. Inflamm Bowel Dis. 2012;18(7):1221-1231. doi: https://doi.org/10.1002/ibd.21854
26. Tian Y, Wang HH. The application value of serological detection of ASCA and ANCA serum level in the diagnosis and treatment of inflammatory bowel disease. Chinese J Lab Med. 2018;41(10):708-711. doi: https://doi.org/10.3760/cma.j.issn.1009-9158.2018.10.002
27. Mitsuyama K, Niwa M, Takedatsu H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304-1310. doi: https://doi.org/10.3748/wjg.v22.i3.1304
28. Aleksandrova EN, Novikov AA, Lukina GV, Parfenov AI. Clinical value of antibodies in inflammatory bowel diseases. Terapevticheskii Arkhiv. 2021;93(2):228-235 (In Russ). doi: https://doi.org/10.26442/00403660.2021.02.200610
29. Kuznetsova DA, Lapin SV, Shchukina OB. The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review). Almanac of Clinical Medicine. 2020;48(6):364-374. (In Russ). doi: https://doi.org/10.18786/2072-0505-2020-48-061
30. Hashash JG, Koutroumpakis F, Anderson AM, et al. Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease. Ann Gastroenterol. 2022;35(6):609-617. doi: https://doi.org/10.20524/aog.2022.0748
31. Chen P, Zhou G, Lin J, et al. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. doi: https://doi.org/10.3389/fmed.2020.00123
32. Smids C, Horjus Talabur Horje CS, Groenen MJM, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52(10):1104-1112. doi: https://doi.org/10.1080/00365521.2017.1344875
33. Bykov AS, Karaulov AV, Tsomartova DA, et al. M cells are the important post in the initiation of immune response in intestine. Russian Journal of Infection and Immunity. 2018;8(3):263-272. (In Russ). doi: https://doi.org/10.15789/2220-7619-2018-3-263-272
34. Shpoliansky M, Roggenbuck D, Pinsker M, et al. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease. Dig Dis Sci. 2021;66(8):2619-2626. doi: https://doi.org/10.1007/s10620-020-06589-5
35. Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an Anti-Integrin ave6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021;160(70):2383-2394.e21. doi: https://doi.org/10.1053/j.gastro.2021.02.019
36. Venkateswaran S, Denson LA, Jurickova I, et al. Neutrophil GM-CSF signaling in inflammatory bowel disease patients is influenced by non-coding genetic variants. Sci Rep. 2019;9(1):9168. doi: https://doi.org/10.1038/s41598-019-45701-2
37. Zurochka AV, Zurochka VA, Dobrynina MA, Gritsenko VA. Immunobiological properties of granulocytemacrophage colony-stimulating factor and synthetic peptides of his active center. Medical Immunology (Russia). 2021;23(5):1031-1054. (In Russ). doi: https://doi.org/10.15789/1563-0625-IPO-2216
38. Duryee MJ, Ahmad R, Eichele DD, et al. Identification of Immunoglobulin G Autoantibody Against MalondialdehydeAcetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. Clin Transl Gastroenterol. 2022;13(4):e00469. doi: https://doi.org/10.14309/ctg.0000000000000469
39. Kovacs M, Muller KE, Papp M, et al. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873-4882. doi: https://doi.org/10.3748/wjg.v20.i17.4873
40. Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. Predicting Outcomes in Pediatric Crohn's Disease for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. Gastroenterology. 2021;160(1):403-436. doi: https://doi.org/10.1053/j.gas-tro.2020.07.065
41. Abu-Freha N, Badarna W, Sigal-Batikoff I, et al. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;18(1):153. doi: https://doi.org/10.1186/s12876-018-0884-x
42. Li BH, Guan X, Vittinghoff E, Gupta N. Comparison of the presentation and course of pediatric inflammatory bowel disease in South Asians with Whites: a single center study in the United States. J Pediatr. 2013;163(4):1211-1213. doi: https://doi.org/10.1016/j.jpeds.2013.04.017
43. Duarte-Silva M, Afonso PC, de Souza PR, et al. Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn's disease. Autoimmunity. 2019;52(1):37-47. doi: https://doi.org/10.1080/08916934.2019.1588889
44. Yorulmaz E, Adali G, Yorulmaz H, et al. The Correlation between New Serological Markers and Disease Phenotype and Activation in Inflammatory Bowel Disease. Middle East J Dig Dis. 2022;14(3):294-303. doi: https://doi.org/10.34172/mejdd.2022.286
45. Chandrakumar A, Georgy M, Agarwal P, et al. Anti-Saccharomyces cerevisiae Antibodies as a Prognostic Biomarker in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2019;69(1):82-87. doi: https://doi.org/10.1097/MPG.0000000000002311
46. Olbj0rn C, Cvancarova Smastuen M, Thiis-Evensen E, et al. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414-419. doi: https://doi.org/10.1080/00365521.2016.1259653
47. Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710-1718. doi: https://doi.org/10.1016/S0140-6736(17)30317-3
48. Torres J, Petralia F, Sato T, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology. 2020;159(1):96-104. doi: https://doi.org/10.1053/j.gastro.2020.03.007
49. Dykes DM, Towbin AJ, Bonkowski E, et al. Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocytemacrophage colony stimulating factor autoantibodies. Inflamm Bowel Dis. 2013;19(10):2146-2154. doi: https://doi.org/10.1097/MIB.0b013e31829706e0
50. Kristensen VA, Cvancarova M, H0ivik ML, et al. Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients — the IBSEN study. Scand J Gastroenterol. 2020;55(4):436-441. doi: https://doi.org/10.1080/00365521.2020.1745879
Review
For citations:
Kamalova A.A., Khanafina M.A., Garina G.A. Clinical and Diagnostic Value of Inflammatory Bowel Diseases' Serological Markers in Children (Literature Review). Pediatric pharmacology. 2023;20(4):309-317. (In Russ.) https://doi.org/10.15690/pf.v20i4.2605
Views:
548
Email this article 